Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bristol-Myers

Merck

Pfizer

Berkshire's latest filing revealed the Oracle of Omaha and his team opening new positions in four pharma giants as of late. From a quality standpoint, all companies seem like a natural fit considering Buffett's reported preference for wide-moat businesses.

Buffett Buys Pharma: Two Out Of Four Seem Compelling

Gilead Sciences

Should you buy these drugmaker stocks for their juicy dividend yields?

3 Pharma Stocks With Dividends Above 4% to Buy Now

AbbVie stock is up 18% since the start of the year and it has gained around 62% from its March lows. Despite the recent rally, AbbVie could offer an upside in the near term, as the company's revenues in the last three quarters have grown by 30%, primarily aided by the Allergan acquisition.

Despite A 65% Rally AbbVie Stock Looks Like It Can Gain More

Autodesk

Cisco Systems

Dominion Energy

Duke Energy

Home Depot

Prudential Financial

Southern Company

AT&T

Unum Group - 6.25% NT REDEEM 15/06/2058 USD 25

Top five holdings add up to 50% of my portfolio. Portfolio currently yields approximately 3.91%.

Eighth Review Of My Dividend Portfolio

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock?

AbbVie (ABBV) Up 30% Since Last Earnings Report: Can It Continue?

Despite solid gains in pharma sales and profits, Big Pharma's overall share value has pretty much stagnated over the past five years—but better days appear to be ahead, in my opinion.

Berkshire Hathaway Makes Big Bet on Pharma

The stock has a high yield -- and it also has something even more important.

Is AbbVie a Great Dividend Stock?

Citigroup

Citizens Financial Group

CVS Health

Chevron

Enterprise Products Partners

Exelon

Diamondback Energy

Marathon Petroleum

NRG Energy

Realty Income Corp

Phillips 66

Valero Energy

Verizon

Williams

In October and July, Kiplinger Today listed Analyst and Kiplinger favorite dividend stocks. Analyst October favorites numbered 25, plus 15 from Kiplinger, with one repeated left 39 total. These 39 stocks ranged from 1.42% to 8.74% in annual yield and ranged from 0.13% to 33.33% in one-year price target upsides per brokers 11/25/20.

A Dividend Cornucopia Of 39 November Kiplinger/Analyst Favorites

Bank of America

General Motors

Kroger

Liberty Latin America

Snowflake

T-Mobile US

In this article we'll run through the Top 10 Stocks Warren Buffett Just Bought. If you're in a hurry to see the hedge fund legend's highest conviction new stock purchases, you can jump straight to the Top 5 Stocks Warren Buffett Just Bought .

Top 10 Stocks Warren Buffett Just Bought

Walgreens

By Bob Ciura with Sure Dividend. The U.S. stock market has come roaring back from the lows seen in March and April, but the broader economy remains on unstable footing.

3 Dividend Aristocrats For Safe Dividends And High Total Returns

Conagra Brands

Cardinal Health

General Mills

Altria

The companies had to reach yield and sales hurdles.

Deep Dive: Only these five dividend stocks made the cut in a ‘safer and better' screen

Wells Fargo

The Dividend Stocks screener at GuruFocus finds 616 dividend stocks held by the gurus as of the writing of this article. Another 19 are listed as over-the-counter stocks.

3 Dividend Stocks Gurus Like

Aflac

A. O. Smith

General Dynamics

Illinois Tool Works

Johnson & Johnson

Lowe's

PepsiCo

Dividend Aristocrats have proven to be reliable investments, no matter what the macro environment looks like. Some of them have continued to raise the dividend at an attractive pace during this pandemic.

Dividend Growth Up To 18%: These Aristocrats Deliver During The Pandemic

Berkshire Hathaway's 13-F filing shows the Oracle of Omaha's bullish on healthcare.

Warren Buffett Just Bought These Stocks

AbbVie Inc. (ABBV) Presents at Wolfe Research Healthcare Conference (Transcript)

AbbVie reported strong Q3 results, the pandemic is not a major headwind for the company. Following another double-digit dividend raise, AbbVie's dividend yield is 5.2%.

5%-Yielding AbbVie: Double-Digit Dividend Raise And A Buffett Endorsement

ABBV is a large biopharmaceutical corporation whose main drug is Humira. ABBV acquired Allergan last year, which provided it with diversification, as well as more substantial size and scale.

AbbVie Should Benefit From A Buffett Bounce

NORTH CHICAGO, Ill., Nov. 18, 2020 /PRNewswire/ -- AbbVie Inc. (NYSE:ABBV) ("AbbVie") announced today the expiration and final results of its offers to exchange (the "Registered Exchange Offers") any and all of its outstanding (i) $30,000,000,000 aggregate principal amount of senior...

AbbVie Announces Expiration and Final Results of Registered Exchange Offers

Warren Buffett's Berkshire Hathaway plowed more than $5 billion in total into AbbVie, Bristol Myers Squibb, Merck, and Pfizer in the third quarter. Close followers of the company won't be surprised, as Buffett has been mulling a bet on the pharmaceutical sector for more than 20 years. "You could've just bought the whole industry and done very well," the famed investor said at Berkshire's annual shareholder meeting in 1997. He was referring to the downturn in drug stocks in the early 1990s, sparked by President Bill Clinton's proposed healthcare reforms. "We didn't do it. It was a mistake."

Warren Buffett's Berkshire Hathaway plowed more than $5 billion into 4 pharma stocks last quarter. He's been teasing a bet on the sector for more than 20 years

The Oracle of Omaha and his investing lieutenants knew what they were doing in buying AbbVie, BMS, Merck, and Pfizer.

Here's Exactly Why Warren Buffett Loaded Up on Big Pharma Stocks

Berkshire Hathaway bought $5.7bn worth of shares in four companies in third quarter

Warren Buffett makes big investment in US pharmaceutical firms

Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) filed its 13F report for the third quarter on Monday this week. The announcement revealed that the Oracle of Omaha made some exciting changes to his portfolio during the reported period, including several investments in pharmaceutical companies.

Has Buffett Become an Expert on Big Pharma?

AbbVie, Merck, Bristol Myers Squibb, and Pfizer are the latest beneficiaries of the "Buffett Effect." The quartet of pharmaceutical stocks jumped in pre-market trading on Tuesday after Warren Buffett's Berkshire Hathaway revealed on Monday that it invested in them last quarter. AbbVie, Merck, and Pfizer gained as much as 2%, and BMS rose as much as 3%, whereas benchmark S&P futures slid around 0.5%.

AbbVie, Merck, and Pfizer shares jump after Warren Buffett's Berkshire Hathaway reveals it bought them last quarter

News for AbbVie Stock (ABBV)